Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


15 April 2021

DECISION Steering Committee Meeting

From 14th – 15th April, the DECISION Steering Committee met again fully virtual. 20 participants exchanged information about progress and results. Great achievement: all ACLARA samples, which are relevant for the work of DECISION, now reached the partner labs. Now the work on these samples can start and we cannot wait to see results.

More news


09 June 2021

DECISION online educational event for patients and public on 9th June 2021!

SAVE THE DATE: We kindly invite you an online educational event about “Therapies for acute decompensation of cirrhosis and ACLF, research needs and future outlook”. Experts from three EU-funded research projects will give talks and answer questions. The event takes place ONLINE on Wednesday, June 9th, from 03.30 – 05.00 PM (CEST). Please register here.

View announcement and programme.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more